Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie
October 23, 2024 01:01 ET
|
Smart Immune
La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée.Le segment randomisé de la phase II de cet essai est en cours.Aucune toxicité limitant la...
Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials
October 23, 2024 01:01 ET
|
Smart Immune
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both...
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 02, 2024 06:00 ET
|
Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...
Smart Immune appoints key new members to its Board of Directors
February 16, 2024 02:00 ET
|
Smart Immune
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell...
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
December 04, 2023 06:46 ET
|
Smart Immune
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage...
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform
November 10, 2023 05:52 ET
|
Smart Immune
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform Clinical-stage T-cell progenitor therapy aims to re-arm the immune system against cancer and infection New class of...
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023
November 02, 2023 09:00 ET
|
Smart Immune
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023 PARIS, France, 02 November 2023 – Smart Immune, a clinical-stage...
Smart Immune Showcases Data and Presentations at ESGCT
October 12, 2023 06:00 ET
|
Smart Immune
PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the...
Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial
September 27, 2023 02:00 ET
|
Smart Immune
No safety concerns in first two patients treatedDesigned to accelerate T-cell reconstitution following haploidentical Hematopoietic Stem Cell Transplantation (HSCT) with post-transplant...
Deux premiers patients atteints de leucémie ont reçu la thérapie SMART101 de Smart Immune dans le cadre de l'essai ReSET-02 de phase I/II
September 27, 2023 02:00 ET
|
Smart Immune
Aucune toxicité observée chez les deux premiers patients traités SMART101 est conçu pour accélérer la reconstitution immunitaire après une greffe de cellules souches haplo-identique suivie d’un...